SCHEMBL16619742

SCHEMBL16619742

COC(=O)Cc1ccc([N+](=O)[O-])cc1Br

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
PDGFRB P09619 1/20 0.46
FGFR1 P11362 1/20 0.46
PDGFRA P16234 1/20 0.46
FLT1 P17948 1/20 0.46
FGFR3 P22607 1/20 0.46
KDR P35968 1/20 0.46
ALDH1A1 P00352 4/20 0.45
GLA P06280 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.44
GAA P10253 3/20 0.44
MAPT P10636 4/20 0.44
PTGS2 P35354 1/20 0.43
PKM P14618 2/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1817138 0.88 POLB (0.47) CYP1A2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL28676925 0.86 MAPT (0.49) CYP1A2ALDH1A1MEN1KMT2AGAA
SCHEMBL18982074 0.86 MEN1 (0.49) CYP1A2ALDH1A1GLAMEN1KMT2A
SCHEMBL1626207 0.84 PDGFRB (0.53) CYP1A2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL31001012 0.84 PDGFRB (0.53) CYP1A2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL29777188 0.84 CYP1A2 (0.68) CYP1A2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL2133926 0.84 CYP1A2 (0.68) CYP1A2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL6597479 0.82 CYP1A2 (0.47) CYP1A2PDGFRBFGFR1PDGFRAFLT1
SCHEMBL1626187 0.82 GAA (0.58) CYP1A2ALDH1A1GLAMEN1KMT2A
SCHEMBL1625685 0.82 MAPT (0.49) CYP1A2PDGFRBFGFR1PDGFRAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2026-01-22 US disclosed
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2025-07-29 US disclosed
US-12168646-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2024-12-17 US disclosed
EP-4472953-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF Nexys Therapeutics, Inc. (US) 2024-12-11 EP disclosed
US-20240383893-A1 Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof HAIHE BIOPHARMA CO., LTD. (CN) 2024-11-21 US disclosed
US-20240279185-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-08-22 US disclosed
EP-4400493-A1 HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF Haihe Biopharma Co., Ltd. (CN) 2024-07-17 EP disclosed
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-06-27 US disclosed
CN-117980293-A Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof 上海海和药物研究开发股份有限公司 2024-05-03 CN disclosed
WO-2023150197-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed
WO-2023036289-A1 HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF 上海海和药物研究开发股份有限公司 2023-03-16 WO disclosed
WO-2017156181-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
WO-2017156181-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
WO-2015049629-A1 IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS Piramal Enterprises Limited (IN) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383893-A1 Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof ENPP1, ENPP2, ENPP3 CYP1A2 4427/4885PDGFRB 2367/4885FGFR1 1221/4885
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 CYP1A2 86/4885PDGFRB 567/4885FGFR1 301/4885
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, NR1H4, CNR1 CYP1A2 249/4885PDGFRB 768/4885FGFR1 544/4885
US-20240279185-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 CYP1A2 86/4885PDGFRB 567/4885FGFR1 301/4885
US-12168646-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 CYP1A2 86/4885PDGFRB 567/4885FGFR1 301/4885
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 CYP1A2 86/4885PDGFRB 567/4885FGFR1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.